Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 2/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | BRD4 | O60885 | 2/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29215500 | 0.91 | POLB (0.67) | SMN1; SMN2POLBMAPK1KMT2AMEN1 | |
| SCHEMBL30311533 | 0.91 | POLB (0.67) | SMN1; SMN2POLBMAPK1KMT2AMEN1 | |
| SCHEMBL2677556 | 0.91 | POLB (0.89) | SMN1; SMN2POLBMAPK1KMT2AMEN1 | |
| SCHEMBL11878483 | 0.90 | POLB (0.97) | SMN1; SMN2POLBMAPK1KMT2AMEN1 | |
| SCHEMBL5656530 | 0.88 | POLB (1.00) | SMN1; SMN2POLBMAPK1KMT2AMEN1 | |
| Capobenic Acid SCHEMBL309384 | 0.88 | POLB (1.00) | SMN1; SMN2POLBMAPK1KMT2AMEN1 | |
| SCHEMBL10790461 | 0.84 | KMT2A (0.77) | SMN1; SMN2POLBMAPK1KMT2AMEN1 | |
| SCHEMBL2926341 | 0.84 | KMT2A (0.77) | SMN1; SMN2POLBMAPK1KMT2AMEN1 | |
| SCHEMBL11740732 | 0.84 | KMT2A (0.67) | SMN1; SMN2POLBMAPK1KMT2AMEN1 | |
| SCHEMBL3199273 | 0.83 | POLB (0.80) | SMN1; SMN2POLBMAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1880711-B1 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD (JP) | 2016-07-20 | — | — | EP | claimed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | claimed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | claimed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | claimed |
| EP-1880711-B1 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1941861-A1 | WRINKLE-IMPROVING AGENT | Shiseido Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035881-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | SMN1; SMN2 24/4885POLB 1408/4885MAPK1 2330/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | SMN1; SMN2 3451/4885POLB 1724/4885MAPK1 2393/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | SMN1; SMN2 29/4885POLB 882/4885MAPK1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.